Eovist
Cancer of the Prostate
University of CincinnatiEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
115 Active assets in the Cancer of the Prostate cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BBB |
Enzalutamide Pfizer | Phase 4 | BBB |
Degarelix Baptist Health South Florida | Phase 3 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Eovist is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →